Spero Therapeutics, Inc. Common Stock
SPROSpero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for bacterial infectious diseases. The company's portfolio includes innovative antibiotics aimed at treating multi-drug resistant infections, addressing significant unmet medical needs in infectious disease care.
Company News
Spero Therapeutics granted 90,000 restricted stock unit awards to a new employee under their 2019 Inducement Equity Incentive Plan, with vesting occurring in four equal annual installments starting December 1, 2025.
Spero Therapeutics announced interim leadership changes, including the appointment of Esther Rajavelu as Interim President and CEO, and Frank Thomas as Chairman of the Board. The company also provided updates on the Phase 3 PIVOT-PO trial of Tebipenem HBr and its financial position.
Spero Therapeutics, a biopharmaceutical company, announced the grant of 227,500 restricted stock unit awards to new employees under its 2019 Inducement Equity Incentive Plan. The RSUs will vest over four years, subject to continued employment.
Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Sp...
